ScreenerHero

AYTU Aytu BioPharma, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · aytubio.com
2.050USD0.00%Mkt Cap: 22.28M $P/E: —

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hype…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap22.28M USD
Enterprise Value14.07M USD
Revenue (TTM)57.57M USD
Gross Profit36.82M USD
Net Income (TTM)-14.25M USD
Revenue/Share4.67 USD
Last Price2.050 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees75
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)13.23
PEG—
EV/EBITDA-3.21
EV/Revenue0.24
P/S0.39
P/B0.62
EPS (TTM)-1.14
EPS (Forward)0.15
52W Range
1.65028% of range3.070
52W High3.070 USD
52W Low1.650 USD
Profitability
Gross Margin63.95%
Oper. Margin-4.82%
EBITDA Margin-7.62%
Profit Margin-24.76%
ROE-40.40%
ROA-13.57%
Growth
Revenue Growth6.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF3.28M USD
CapEx (TTM)29.00K USD
FCF Margin9.72%
FCF Yield25.13%
Net Debt-8.20M USD
Net Debt/EBITDA1.87
Balance Sheet
Debt/Equity0.48
Current Ratio1.13
Quick Ratio0.90
Book Value/Sh3.29 USD
Cash/Share2.42 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 9, 2020
Splits
Last Split1:20
Split DateJan 6, 2023
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.667 USD
Upside (mean)+371.5%
Target Range7.000 USD – 15.00 USD
7.000+371.5% to mean15.00
# Analysts3
Ownership
Shares Out.10.87M
Float7.69M
Insiders8.16%
Institutions35.51%
Short Interest
Short Ratio12.1d
Short % Float3.33%
Short % Out.2.87%
Shares Short311.61K
Short (prev mo.)321.54K
Technical
SMA 502.216 (-7.5%)
SMA 2002.376 (-13.7%)
Beta0.18
S&P 52W Chg16.45%
Avg Vol (30d)42.48K
Avg Vol (10d)53.85K
Technical Indicators
RSI (14)39.6
MACD-0.0403
MACD Signal-0.0279
MACD Hist.-0.0124
BB Upper2.323 USD
BB Middle2.125 USD
BB Lower1.927 USD
BB Width18.62%
ATR (14)0.0996 USD
Vol Ratio (20d)0.11x